In agreement, neutralizing antibodies against IL-17A and IL-23 represent effective state-of-the-art therapies for the treatment of patients with psoriasis, whereas antagonizing IL-36 receptor antibodies are currently being investigated as a new therapy approach for psoriasis (6). Here, IL23A is linked to psoriasis.